Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Bladerunner17 who wrote (223)	10/10/2018 12:45:36 PM
From: semi_infinite	Read Replies (1) \| Respond to of 294

Lot of guess work equals thinking so caveat emptor. It could be that plus a combination of crowded trade with high expectations. After all, I recall reading a paper last year where Celgene scientists conceded that TTI-621 did better than their molecule in non-human lab testings. I thought the expectations were low enough already. Apparently not. Still gathering sold shares, with difficulty. I am a deep water fish and sellers need to be less stubborn notwithstanding the fundamental support of MF and Sezary prob of success. Is TTI-621 still being tried in AML and ALL patients? I get the impression from trial docs that they are included in the N=260 expansion/revisions.